# PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)

> **NCT07267234** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital of Soochow University** · enrollment: 65 (estimated)

## Conditions studied

- Solid Cancer
- Lymphopenia
- Radiotherapy
- Immune Checkpoint Inhibitor

## Interventions

- **DRUG:** PD -1/PD-L1 monoclonal antibody

## Key facts

- **NCT ID:** NCT07267234
- **Lead sponsor:** Second Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07267234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07267234, "PRaG-1 Plus PRaG Therapy in Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07267234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*